Biotechs generally need access to a lot of capital in order to bring their therapeutics to market. The traditional IPO route was the classic way a Biotech was able to access the public market. Today there is another option - a de-SPAC merger with a SPAC. There are many reasons to choose one approach over the other - valuation, cost of capital, dilution, etc. but now Biotechs looking to go public have another way to do it. Our client DermTech is a great example of a very successful healthcare SPAC.
| less than a minute read
SPACs are an Increasingly Attractive Option for Biotech Companies
Get in touch
Get in touch
Biotechnology startups can increasingly go public on their own terms as investors and blank-check companies clamor for access to the hottest new drugmakers.
Get in touch
Get in touch
/Passle/5f7c32f353548911309c42df/MediaLibrary/Images/2024-11-26-19-02-08-026-67461b30530ccc05630285ca.jpg)
With intangible assets representing over 90% of an AI company’s value, an effective intellectual property strategy is essential to...
Latest Insights
/Passle/5f7c32f353548911309c42df/SearchServiceImages/2024-12-20-06-29-00-813-67650eac8b43d2162bbe0c4b.jpg)
/Passle/5f7c32f353548911309c42df/SearchServiceImages/2024-12-19-16-52-34-384-67644f522e5b24efe2d24c81.jpg)
/Passle/5f7c32f353548911309c42df/SearchServiceImages/2024-12-17-22-28-22-746-6761fb064f363822418cba43.jpg)
/Passle/5f7c32f353548911309c42df/SearchServiceImages/2024-12-16-16-00-43-722-67604eabe47d4e3f62ee4dc0.jpg)